As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk's flagship obesity care treatment, Wegovy, recently received approval in China. Obesity is a big medical issue in China, estimated to affect hundreds of millions of people. While ...